Drug Shortage Report for JAMP RIVASTIGMINE
| Report ID | 154940 |
| Drug Identification Number | 02485389 |
| Brand name | JAMP RIVASTIGMINE |
| Common or Proper name | Rivastigmine Hydrogen Tartrate Capsules |
| Company Name | JAMP PHARMA CORPORATION |
| Market Status | MARKETED |
| Active Ingredient(s) | RIVASTIGMINE |
| Strength(s) | 4.5MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL |
| Packaging size | 56 (blister pack) |
| ATC code | N06DA |
| ATC description | ANTI-DEMENTIA DRUGS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-02-09 |
| Actual start date | |
| Estimated end date | 2022-05-20 |
| Actual end date | 2022-05-30 |
| Shortage status | Resolved |
| Updated date | 2022-06-13 |
| Company comments | FORMAT 100 AVAILABLE |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 1310 RUE NOBEL BOUCHERVILLE, QUEBEC CANADA J4B 5H3 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v8 | 2022-06-13 | French | Compare |
| v7 | 2022-06-13 | English | Compare |
| v6 | 2022-05-17 | French | Compare |
| v5 | 2022-05-17 | English | Compare |
| v4 | 2022-03-08 | French | Compare |
| v3 | 2022-03-08 | English | Compare |
| v2 | 2022-02-14 | French | Compare |
| v1 | 2022-02-14 | English | Compare |
Showing 1 to 8 of 8